Fibrocell Science Inc

Fibrocell Science — Investor Presentation (July 2016)

20 slides from Fibrocell Science's investor presentation, Jul 12, 2016

  1. Slide 1: Corporate Presentation July 12, 2016

    Corporate Presentation July 12, 2016

  2. Slide 2: Forward-Looking Statements

    This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among ot

  3. Slide 3: Company Highlights

    Company Highlights •Autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue • FCX-007 — gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Actively recruiting adult subjects in Phase

  4. Slide 4: Autologous Fibroblasts as a Platform for Therapy

    Autologous Fibroblasts as a Platform for Therapy •Most common cell in skin and connective tissue  Ideal delivery vehicle to administer protein of interest locally •Key advantages of our autologous fibroblast platform for creating cell and gene therapies: Localized administration avoids side effect

  5. Slide 5: Personalized Biologics Approach

    Personalized Biologics Approach 5

  6. Slide 6: Development Pipeline

    Development Pipeline 6 Personalized Biologics Indication Research Pre-Clinical Development Phase I Phase II Phase III FCX-007 Orphan Product Candidate Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Orphan Product Candidate Linear Scleroderma Gene Therapy Program Arthritis

  7. Slide 7: Recessive Dystrophic Epidermolysis Bullosa

    Recessive Dystrophic Epidermolysis Bullosa 7 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate • Current treatments only ad

  8. Slide 8: FCX-007 Providing Hope for RDEB Patients

    FCX-007 Providing Hope for RDEB Patients 8 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1 

  9. Slide 9: Detection of COL7 Expression by Immunofluorescence

    9 Detection of COL7 Expression by Immunofluorescence (Magnification 20x) • In vitro COL7 expression noted from FCX-007 replicates (red) • FCX-007 expresses higher levels of COL7 than normal human dermal fibroblasts (NHDF) as depicted by a brighter signal • No expression of COL7 in RDEB-positive fibr

  10. Slide 10: COL7 Expression Confirmation

    COL7 Expression Confirmation 10 Culture supernatant evaluated for in vitro COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruckner-Tuder

  11. Slide 11: Long-lasting COL7 Persistence Expected

    • Autologous cells having less rejection risk • Direct administration of FCX-007 to the upper dermis ensures COL7 is expressed in the basement membrane zone where anchoring fibrils are formed • The integrative nature of the lentivirus allows the COL7A1 gene to be passed to daughter cells as FCX-007

  12. Slide 12: FCX-007 Phase I/II Clinical Trial Design

    FCX-007 Phase I/II Clinical Trial Design 12 Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Objectives Primary 1) To evaluate the safety of FCX-007 Secondary 1) To evaluate mechanism of action of FCX

  13. Slide 13: Linear Scleroderma

    Linear Scleroderma 13 Disease Epidemiology • Excess production of collagen I and III characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions ap

  14. Slide 14: FCX-013 Development Progressing

    FCX-013 Development Progressing 14 •Product profile Autologous fibroblasts genetically modified using lentivirus and encoded for a protein responsible for breaking down excess collagen I and III  Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to control protein expression •Proof-of-

  15. Slide 15: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study 15 • Study Design  Bleomycin treated SCID mouse model  N=30 mice over test and control groups  Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result  Bleomycin treatment resulted in skin

  16. Slide 16: RheoSwitch Control

    • FCX-013 employs Intrexon’s RheoSwitch Therapeutic System® (RTS®)  The RTS® biologic switch is activated by an orally- administered activator ligand (AL) that provides the ability to control level and timing of protein expression • Enhances the safety profile of FCX-013 by providing control over t

  17. Slide 17: Gene Therapy Research Program for Arthritis

    Gene Therapy Research Program for Arthritis 17 • Deliver protein therapy locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy • Combines Fibrocell’s autologous fibroblast technology with Intrexon’s cellular engineering to develo

  18. Slide 18: Milestones & Corporate Information

    Milestones & Corporate Information 18 •Cash = $13.1 million at 31 Mar 2016 (unaudited) •43.9 million common shares of FCSC outstanding at 31 Mar 2016  5.3 million warrants; 4.0 million options Milestones Timing FCX-007 Phase I/II Trial Initial Phase I data expected 2H17 FCX-013 IND Submission Expec

  19. Slide 19: Company Highlights

    Company Highlights •Autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue • FCX-007 — gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Actively recruiting adult subjects in Phase

  20. Slide 20: References

    References 1Data on file. Fibrocell Science, Inc. 2The Dystrophic Epidermolysis Research Association of America (DebRA). DEB brochure, page 6: http://www.debra.org/pdfs/Debra-of-America-Brochure.pdf; accessed 07/20/15. 3DEBRA International. What is EB Infographic: http://www.debra-international.org/

Fibrocell Science — Investor Presentation (July 2016) on 6ix